Page 132 - 《中国药房》2025年9期

loss drugs in overweight and obesity：a network meta- the United States[J]. J Manag Care Spec Pharm，2024，30
analysis[J]. Obesity （Silver Spring），2024，32（5）：840-856. （2）：153-162.
[14] TAN B，PAN X H，CHEW H S J，et al. Efficacy and safety [24] LUMBRERAS A G，TAN M S，VILLA-ZAPATA L，et al.
of tirzepatide for treatment of overweight or obesity. A Cost-effectiveness analysis of five anti-obesity medica‐
systematic review and meta-analysis[J]. Int J Obes tions from a US payer’s perspective[J]. Nutr Metab Car‐
（Lond），2023，47（8）：677-685. diovasc Dis，2023，33（6）：1268-1276.
[15] ALKHEZI O S，ALAHMED A A，ALFAYEZ O M，et al. [25] VALENTINE W J，HOOG M，MODY R，et al. Long-term
Comparative effectiveness of glucagon-like peptide-1 re‐ cost-effectiveness analysis of tirzepatide versus semaglu‐
ceptor agonists for the management of obesity in adults tide 1.0 mg for the management of type 2 diabetes in the
without diabetes：a network meta-analysis of randomized United States[J]. Diabetes Obes Metab，2023，25（5）：
clinical trials[J]. Obes Rev，2023，24（3）：e13543. 1292-1300.
[16] KARAGIANNIS T，MALANDRIS K，AVGERINOS I， [26] ZHANG X T，MCADAM MARX C. Short-term cost-
et al. Subcutaneously administered tirzepatide vs semaglu‐ effectiveness analysis of tirzepatide for the treatment of
tide for adults with type 2 diabetes：a systematic review type 2 diabetes in the United States[J]. J Manag Care Spec
and network meta-analysis of randomised controlled trials Pharm，2023，29（3）：276-284.
[J]. Diabetologia，2024，67（7）：1206-1222. [27] MARSO S P，DANIELS G H，BROWN-FRANDSEN K，
[17] YAO H Q，ZHANG A Q，LI D L，et al. Comparative effec‐ et al. Liraglutide and cardiovascular outcomes in type 2
tiveness of GLP-1 receptor agonists on glycaemic control， diabetes[J]. N Engl J Med，2016，375（4）：311-322.
body weight，and lipid profile for type 2 diabetes：syste- [28] KRISTENSEN S L，RØRTH R，JHUND P S，et al. Cardio‐
matic review and network meta-analysis[J]. BMJ，2024， vascular，mortality，and kidney outcomes with GLP-1 re‐
384：e076410. ceptor agonists in patients with type 2 diabetes：a syste-
[18] DING Y N，SHI Y F，GUAN R F，et al. Evaluation and matic review and meta-analysis of cardiovascular outcome
comparison of efficacy and safety of tirzepatide and trials[J]. Lancet Diabetes Endocrinol，2019，7（10）：776-785.
semaglutide in patients with type 2 diabetes mellitus：a [29] SATTAR N，MCGUIRE D K，PAVO I，et al. Tirzepatide
Bayesian network meta-analysis[J]. Pharmacol Res，2024， cardiovascular event risk assessment：a pre-specified meta-
199：107031. analysis[J]. Nat Med，2022，28（3）：591-598.
[19] TSUKAMOTO S，TANAKA S，YAMADA T，et al. Effect [30] American Diabetes Association Professional Practice
of tirzepatide on glycaemic control and weight loss com‐ Committee. 8. Obesity and weight management for the
pared with other glucagon-like peptide-1 receptor agonists prevention and treatment of type 2 diabetes：standards of
in Japanese patients with type 2 diabetes mellitus[J]. Dia‐ care in diabetes：2024[J]. Diabetes Care，2024，47（Suppl.
betes Obes Metab，2024，26（1）：262-274. 1）：S145-S157.
[20] XIE Z Y，HU J，GU H Y，et al. Comparison of the efficacy [31] 中华医学会内分泌学分会. 肥胖患者的长期体重管理及
and safety of 10 glucagon-like peptide-1 receptor agonists 药物临床应用指南：2024 版[J]. 中华内分泌代谢杂志，
as add-on to metformin in patients with type 2 diabetes：a 2024，40（7）：545-564.
systematic review[J]. Front Endocrinol （Lausanne），2023， [32] 国家卫生健康委. 国家卫生健康委办公厅关于印发肥胖
14：1244432. 症诊疗指南（2024 年版）的通知[EB/OL].（2024-10-12）
[21] NAUCK M A，MIRNA A E A，QUAST D R. Meta- [2025-03-06]. https：//www.gov.cn/zhengce/zhengceku/
analysis of head-to-head clinical trials comparing incretin- 202410/content_6981734.htm.
based glucose-lowering medications and basal insulin：an [33] 卢伟涛，何家汝，陈文瑛 . 基于 FAERS 数据库的司美格
update including recently developed glucagon-like pep‐ 鲁肽药品不良事件信号挖掘[J]. 中国药房，2022，33
tide-1 （GLP-1） receptor agonists and the glucose- （15）：1865-1869，1875.
dependent insulinotropic polypeptide/GLP-1 receptor [34] MIZUMOTO J. Tirzepatide-induced injection site reaction
co-agonist tirzepatide[J]. Diabetes Obes Metab，2023，25 [J]. Cureus，2023，15（9）：e45181.
（5）：1361-1371. [35] LIU L Y. A real-world data analysis of tirzepatide in the
[22] ZAAZOUEE M S，HAMDALLAH A，HELMY S K，et al. FDA adverse event reporting system （FAERS） database
Semaglutide for the treatment of type 2 diabetes mellitus： [J]. Front Pharmacol，2024，15：1397029.
a systematic review and network meta-analysis of safety [36] HU S S，SHI C Y，MA Y H，et al. Cost-utility analysis and
and efficacy outcomes[J]. Diabetes Metab Syndr，2022，16 drug pricing for tirzepatide for type 2 diabetes in the
（6）：102511. Chinese market compared with semaglutide[J]. Diabetes
[23] MODY R，VALENTINE W J，HOOG M，et al. Tirzepatide Obes Metab，2024，26（8）：3176-3190.
10 and 15 mg vs semaglutide 2.0 mg：a long-term cost- （收稿日期：2024-10-31 修回日期：2025-03-26）
effectiveness analysis in patients with type 2 diabetes in （编辑：陈 宏）

· 1146 · China Pharmacy 2025 Vol. 36 No. 9 中国药房 2025年第36卷第9期